News Releases News Releases Year None2026202520242023202220212020201920182016 June 4, 2026 NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers June 1, 2026 NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026 May 7, 2026 NextCure Provides Business Update and Reports First Quarter 2026 Financial Results May 4, 2026 NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers April 21, 2026 NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026 April 7, 2026 NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer March 31, 2026 NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026 March 5, 2026 NextCure Provides Business Update and Reports Full Year 2025 Financial Results January 23, 2026 NextCure Provides Business Update Tools
News Releases Year None2026202520242023202220212020201920182016 June 4, 2026 NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers June 1, 2026 NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026 May 7, 2026 NextCure Provides Business Update and Reports First Quarter 2026 Financial Results May 4, 2026 NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers April 21, 2026 NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026 April 7, 2026 NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer March 31, 2026 NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026 March 5, 2026 NextCure Provides Business Update and Reports Full Year 2025 Financial Results January 23, 2026 NextCure Provides Business Update
